Document Detail


5-alpha reductase inhibitors and erectile dysfunction: the connection.
MedLine Citation:
PMID:  19090946     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Benign prostatic hyperplasia (BPH) is a common problem affecting middle-aged and elderly men. First-line medical therapy includes alpha 1blockers and 5alpha-reductase inhibitors (5ARIs), such as finasteride and dutasteride. 5ARI use has been associated with adverse sexual outcomes, including erectile dysfunction (ED), ejaculatory dysfunction (EjD), and decreased libido. AIM: To clarify the association between sexual adverse effects (AEs) and 5ARIs through review of literature concerning 5ARIs and to review the proposed mechanisms of these effects. METHODS: A comprehensive literature review, using MEDLINE and PUBMED search engines, was conducted for all publications concerning 5ARIs and sexual AEs. MAIN OUTCOME MEASURE: Sexual adverse effects, such as ED, EjD, and decreased libido, were the measured outcomes of this literature review. RESULTS: Sexual AEs are reported in clinical trials at rates of 2.1% to 38%. The most common sexual AE is ED, followed by EjD and decreased libido. These effects occur early in therapy and attenuate over time. A proposed mechanism for sexual dysfunction involves decreased nitric oxide synthase activity due to decreased dihydrotestosterone. CONCLUSIONS: The connection between 5ARIs and sexual dysfunction is apparent upon review of the literature. Though theories have been proposed, little is known about the exact mechanisms behind 5ARI-related sexual dysfunction. Since the connection between 5ARIs and sexual AEs is established in the literature, future research should be directed toward deciphering the pathophysiologic mechanisms. When more basic science knowledge is attained in this area, the focus can shift toward prevention and treatment.
Authors:
Fikret Erdemir; Andrew Harbin; Wayne J G Hellstrom
Related Documents :
19663116 - Frequency of thromboembolic events associated with thalidomide in the non-cancer settin...
23953086 - Systematic reviews of complex interventions: framing the review question.
2860076 - Prevention and treatment of bronchospasm using an extempore combination of salbutamol a...
17845176 - Isotretinoin-induced agranulocytosis.
15999316 - Infarction of an accessory spleen presenting as acute abdomen in a neonate.
9150526 - Traumatic cataract and wieger's ligament.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The journal of sexual medicine     Volume:  5     ISSN:  1743-6109     ISO Abbreviation:  -     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-18     Completed Date:  2009-04-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101230693     Medline TA:  J Sex Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2917-24     Citation Subset:  IM    
Affiliation:
Tulane University-Department of Urology, New Orleans, LA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / adverse effects,  therapeutic use
Azasteroids / adverse effects,  therapeutic use
Drug Therapy, Combination
Ejaculation / drug effects
Erectile Dysfunction / chemically induced*
Finasteride / adverse effects,  therapeutic use
Humans
Libido / drug effects
Male
Prostatic Hyperplasia / drug therapy*
Testosterone 5-alpha-Reductase / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Azasteroids; 0/dutasteride; 98319-26-7/Finasteride; EC 1.3.99.5/Testosterone 5-alpha-Reductase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improvement of chronic pain by treatment of erectile dysfunction.
Next Document:  Interaction of chronic sleep restriction and circadian system in humans.